Spotlight: Myasthenia Gravis

'MG is a relapsing and remitting condition with variable severity and remission more likely in the early years'

clock • 4 min read

Vitality's John Downes examines the history, variations, symptoms and underwriting considerations of Myasthenia Gravis.

Myasthenia Gravis (MG) is a relatively rare autoimmune disease that causes muscle weakness, especially in the eyes and face but it can affect other parts of the body as well. MG interferes with the body's ability to send messages between the nerves and the muscles causing the muscles to become weak and easily fatigued. The name derives from the Greek/Latin words (myo) for muscle, (asthenia) weakness and the Latin word (gravis) for ‘weighty' or ‘heavy'. While the disease was first described by 17th century English physician, Thomas Willis, it was largely ignored until the first modern des...

To continue reading this article...

Join COVER for free

  • Unlimited access to real-time news, key trend analysis and industry insights.
  • Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
  • Receive breaking news stories straight to your inbox in the daily newsletter.
  • Members only access to monthly programme 'The COVER Review'
  • Be the first to hear about our CPD accredited events and awards programmes.

Join now

 

Already a Cover member?

Login

More on Underwriting

The COVER Review: claims, vulnerable customers, CPD

The COVER Review: claims, vulnerable customers, CPD

Week commencing 15 June 2026

COVER
clock 22 June 2026 • 1 min read
Aviva updates non-medical underwriting limits

Aviva updates non-medical underwriting limits

Aiming to improve turnaround times

Cameron Roberts
clock 18 June 2026 • 1 min read
Aviva adds AI underwriting tool to CIC

Aviva adds AI underwriting tool to CIC

Next focus will be on income protection

Jaskeet Briah
clock 18 March 2026 • 1 min read